Sequential dose‐dense doxorubicin and ifosfamide for advanced soft tissue sarcomas

Abstract

Sequential administration of dose-dense DX and high-dose IF is feasible and exhibits an acceptable hematologic toxicity profile and a level of activity that is within the range described for schedules that combine high-dose IF with an anthracycline.